{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:52:22Z","timestamp":1794268342882,"version":"4.9.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Tick-borne encephalitis (TBE), a viral infectious disease affecting the central nervous system, potentially resulting in prolonged neurological symptoms and other long-term sequelae. Case identification can be challenging as TBE can be associated with non-specific symptoms, and even in cases consistent with typical TBE symptoms, the rate of laboratory testing to confirm cases is unknown. This study assessed real-world TBE laboratory testing rates across Germany.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this retrospective cross-sectional study, physicians provided data on TBE decision-making, laboratory testing (serological), and diagnostics behavior via in-depth qualitative interviews (N\u2009=\u200912) or a web-based quantitative survey of their patient medical records (N\u2009=\u2009166). Hospital-based physicians who\u00a0specialized in infectious disease, intensive care unit, emergency room, neurology, or pediatrics with experience managing and ordering testing for patients with meningitis, encephalitis, or non-specific central nervous system symptoms in the past 12\u00a0months were included. Data were summarized via descriptive statistics. TBE testing and positivity rates were assessed for the aggregate sample of 1400 patient charts and reported by presenting symptoms, region, and tick bite exposure.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>TBE testing rates ranged from 54.0% (non-specific neurological symptoms only) to 65.6% (encephalitis symptoms only); the percentage of TBE positive results ranged from 5.3% (non-specific neurological symptoms only) to 36.9% (meningitis symptoms only). TBE testing rates were higher among those with a tick bite history and\/or who presented with headache, high fever, or flu-like symptoms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The findings of this study suggest that patients with typical TBE symptoms are likely under-tested, thus likely leading to under-diagnosis in Germany. To ensure appropriate case identification, TBE testing should be consistently integrated into routine practice for all patients who present with relevant symptoms or exposure to common risk factors.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-023-08101-6","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T15:04:14Z","timestamp":1678201454000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Evaluation of under-testing and under-diagnosis of tick-borne encephalitis in Germany"],"prefix":"10.1186","volume":"23","author":[{"given":"Katharina","family":"Schley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Friedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pilz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget L.","family":"Balkaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine C.","family":"Maculaitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudius","family":"Malerczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,7]]},"reference":[{"key":"8101_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2019.01.004","volume":"62","author":"N Riccardi","year":"2019","unstructured":"Riccardi N, Antonello RM, Luzzati R, Zajkowska J, Di Bella S, Giacobbe DR. Tick-borne encephalitis in Europe: a brief update on epidemiology, diagnosis, prevention, and treatment. Eur J Intern Med. 2019;62:1\u20136. https:\/\/doi.org\/10.1016\/j.ejim.2019.01.004.","journal-title":"Eur J Intern Med"},{"key":"8101_CR2","doi-asserted-by":"publisher","first-page":"430","DOI":"10.12998\/wjcc.v3.i5.430","volume":"3","author":"P Bogovic","year":"2015","unstructured":"Bogovic P, Strle F. Tick-borne encephalitis: a review of epidemiology, clinical characteristics, and management. World J Clin Cases. 2015;3:430\u201341. https:\/\/doi.org\/10.12998\/wjcc.v3.i5.430.","journal-title":"World J Clin Cases"},{"key":"8101_CR3","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2018.23.45.1800201","author":"J Beaute","year":"2018","unstructured":"Beaute J, Spiteri G, Warns-Petit E, Zeller H. Tick-borne encephalitis in Europe, 2012 to 2016. Euro Surveill. 2018. https:\/\/doi.org\/10.2807\/1560-7917.ES.2018.23.45.1800201.","journal-title":"Euro Surveill"},{"key":"8101_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taw018","author":"R Steffen","year":"2016","unstructured":"Steffen R. Epidemiology of tick-borne encephalitis (TBE) in international travellers to Western\/Central Europe and conclusions on vaccination recommendations. J Travel Med. 2016. https:\/\/doi.org\/10.1093\/jtm\/taw018.","journal-title":"J Travel Med"},{"key":"8101_CR5","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1111\/ene.13356","volume":"24","author":"P Taba","year":"2017","unstructured":"Taba P, Schmutzhard E, Forsberg P, Lutsar I, Ljostad U, Mygland A, et al. EAN consensus review on prevention, diagnosis and management of tick-borne encephalitis. Eur J Neurol. 2017;24:1214-e61. https:\/\/doi.org\/10.1111\/ene.13356.","journal-title":"Eur J Neurol"},{"key":"8101_CR6","unstructured":"Robert Koch-Institut (RKI). Risikogebiete der Fr\u00fchsommer-Meningoenzephalitis. Epid Bull 2001;16:105\u20139."},{"key":"8101_CR7","unstructured":"Encephalitis society. Tick-borne encephalitis. https:\/\/www.encephalitis.info\/tick-borne-encephalitis. Accessed: June 13, 2022."},{"key":"8101_CR8","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.idc.2008.03.013","volume":"22","author":"R Kaiser","year":"2008","unstructured":"Kaiser R. Tick-borne encephalitis. Infect Dis Clin North Am. 2008;22:561\u201375. https:\/\/doi.org\/10.1016\/j.idc.2008.03.013.","journal-title":"Infect Dis Clin North Am"},{"key":"8101_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910615","author":"M Gudowska-Sawczuk","year":"2021","unstructured":"Gudowska-Sawczuk M, Mroczko B. Selected biomarkers of tick-borne encephalitis: a review. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms221910615.","journal-title":"Int J Mol Sci"},{"key":"8101_CR10","unstructured":"Kaiser R et al. Fr\u00fchsommer-Meningoenzephalitis (FSME), S1-Leitlinie, 2020 [Tick-Borne Encephalitis (TBE), S1-Guideline, 2020], in: Deutsche Gesellschaft f\u00fcr Neurologie (ed.), Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie [German Society of Neurology (ed.), Guidelines for diagnostics and therapy in neurology]. www.dgn.org\/leitlinien. Accessed January 13, 2023."},{"key":"8101_CR11","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.vaccine.2020.12.047","volume":"39","author":"K Schley","year":"2021","unstructured":"Schley K, Malerczyk C, Beier D, Schiffner-Rohe J, von Eiff C, Hackl D, et al. Vaccination rate and adherence of tick-borne encephalitis vaccination in Germany. Vaccine. 2021;39:830\u20138. https:\/\/doi.org\/10.1016\/j.vaccine.2020.12.047.","journal-title":"Vaccine"},{"key":"8101_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.25646\/10855","volume":"49","author":"T Rieck","year":"2022","unstructured":"Rieck T, Steffen A, Feig M, Siedler A. Impfquoten bei Erwachsenen in Deutschland\u2014Aktuelles aus der KV-Impfsurveillance [Vaccination rates in adults in Germany\u2014News from the KV-vaccination surveillance]. Epid Bull. 2022;49:3\u201323. https:\/\/doi.org\/10.25646\/10855.","journal-title":"Epid Bull."},{"key":"8101_CR13","doi-asserted-by":"publisher","first-page":"7335","DOI":"10.1016\/j.vaccine.2022.10.075","volume":"40","author":"M Ghiani","year":"2022","unstructured":"Ghiani M, Hagemann C, Friedrich J, Maywald U, Wilke T, von Eiff C, et al. Can risk area designation help increase vaccination coverage for Tick-Borne Encephalitis? Evidence from German claims data. Vaccine. 2022;40:7335\u201342. https:\/\/doi.org\/10.1016\/j.vaccine.2022.10.075.","journal-title":"Vaccine"},{"key":"8101_CR14","doi-asserted-by":"publisher","unstructured":"Robert Koch-Institut (RKI). FSME: Risikogebiete in Deutschland (Stand: January 2021). Epid Bull 2021;9:3\u201320. https:\/\/doi.org\/10.25646\/8079.","DOI":"10.25646\/8079"},{"key":"8101_CR15","doi-asserted-by":"publisher","unstructured":"Robert Koch-Institut (RKI). FSME: Risikogebiete in Deutschland (Stand: January 2022). Epid Bull. 2022;9:3\u201321. https:\/\/doi.org\/10.25646\/9750.","DOI":"10.25646\/9750"},{"key":"8101_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/tropicalmed5030117","author":"M Ricco","year":"2020","unstructured":"Ricco M, Gualerzi G, Ranzieri S, Ferraro P, Bragazzi NL. Knowledge, attitudes, practices (KAP) of Italian occupational physicians towards tick borne encephalitis. Trop Med Infect Dis. 2020. https:\/\/doi.org\/10.3390\/tropicalmed5030117.","journal-title":"Trop Med Infect Dis."},{"key":"8101_CR17","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1093\/jme\/tjaa087","volume":"58","author":"RJ Eisen","year":"2021","unstructured":"Eisen RJ, Paddock CD. Tick and tickborne pathogen surveillance as a public health tool in the United States. J Med Entomol. 2021;58:1490\u2013502. https:\/\/doi.org\/10.1093\/jme\/tjaa087.","journal-title":"J Med Entomol"},{"key":"8101_CR18","doi-asserted-by":"publisher","first-page":"e0224044","DOI":"10.1371\/journal.pone.0224044","volume":"14","author":"JP Borde","year":"2019","unstructured":"Borde JP, Kaier K, Hehn P, Bohmer MM, Kreusch TM, Dobler G. Tick-borne encephalitis virus infections in Germany. Seasonality and in-year patterns. A retrospective analysis from 2001\u20132018. PLoS ONE. 2019;14:e0224044. https:\/\/doi.org\/10.1371\/journal.pone.0224044.","journal-title":"PLoS ONE"},{"key":"8101_CR19","unstructured":"Association of the Scientific Medical Societies. Clinical pathway\u2014FSME. https:\/\/register.awmf.org\/assets\/guidelines\/030-035l_S1_Fruehsommer_Meningoenzephalitis_FSME_2020-02.pdf. Accessed December 23, 2022."},{"key":"8101_CR20","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.tmaid.2013.07.003","volume":"11","author":"M Haditsch","year":"2013","unstructured":"Haditsch M, Kunze U. Tick-borne encephalitis: a disease neglected by travel medicine. Travel Med Infect Dis. 2013;11:295\u2013300. https:\/\/doi.org\/10.1016\/j.tmaid.2013.07.003.","journal-title":"Travel Med Infect Dis"},{"key":"8101_CR21","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.ttbdis.2019.02.015","volume":"10","author":"LE Nigrovic","year":"2019","unstructured":"Nigrovic LE, Neville DN, Balamuth F, Bennett JE, Levas MN, Garro AC, et al. A minority of children diagnosed with Lyme disease recall a preceding tick bite. Ticks Tick Borne Dis. 2019;10:694\u20136. https:\/\/doi.org\/10.1016\/j.ttbdis.2019.02.015.","journal-title":"Ticks Tick Borne Dis"},{"key":"8101_CR22","doi-asserted-by":"publisher","first-page":"100103","DOI":"10.1016\/j.lanepe.2021.100103","volume":"6","author":"A Ullrich","year":"2021","unstructured":"Ullrich A, Schranz M, Rexroth U, Hamouda O, Schaade L, Diercke M, et al. Impact of the COVID-19 pandemic and associated non-pharmaceutical interventions on other notifiable infectious diseases in Germany: an analysis of national surveillance data during week 1\u20132016 - week 32\u20132020. Lancet Reg Health Eur. 2021;6:100103. https:\/\/doi.org\/10.1016\/j.lanepe.2021.100103.","journal-title":"Lancet Reg Health Eur."},{"issue":"7","key":"8101_CR23","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.3390\/microorganisms10071283","volume":"10","author":"M Kunze","year":"2022","unstructured":"Kunze M, Banovi\u0107 P, Bogovi\u010d P, Briciu V, \u010civljak R, Dobler G, et al. Recommendations to improve tick-borne encephalitis surveillance and vaccine uptake in Europe. Microorganisms. 2022;10(7):1283. https:\/\/doi.org\/10.3390\/microorganisms10071283.","journal-title":"Microorganisms"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08101-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08101-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08101-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T15:05:01Z","timestamp":1678201501000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08101-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,7]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8101"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08101-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,7]]},"assertion":[{"value":"24 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors affirm that the research study was conducted in accordance with the Declaration of Helsinki of the World Medical Association. The study was granted an exemption determination by Sterling IRB (Atlanta, GA, US) on July 9, 2020 (IRB ID: 8176-JKen-Opurum) based on US 45 CFR \u00a746.104(d). All participants provided their informed consent prior to participating in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study was conducted under a research contract between Pfizer Inc. and Cerner Enviza and the study was funded by Pfizer Inc. KS and JF are employees of Pfizer Pharma GmbH and may own stocks or stock options. AP is an employee of Pfizer Corporation Austria Gesellschaft m.b.H. and may own stocks or stock options. LH is an employee of Pfizer Inc. and may own stocks or stock options. BLB and MCM are employees of Cerner Enviza. CM is an employee of Pfizer Pharma GmbH and may own stocks or stock options.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"139"}}